Drugs Targeted for Upgrade

Pro-Pharmaceuticals is working to upgrade seven of the most widely used — but highly toxic — anti-cancer drugs. For each of these agents, clinicians would welcome an improvement in their therapeutic efficacy. Equally or more beneficial would be an effort to substantially decrease their well-documented toxicity.

Beside causing severe discomfort and a sharp decline in quality of life, these drugs may induce severe blood toxicity, gastrointestinal hemorrhage or, in rare cases, death.

Drugs currently selected by Pro-Pharmaceuticals for upgrade are among the most commonly prescribed and carry some of the poorest safety profiles:

5-Fluorouracil
Irinotecan
Doxorubicin
Paclitaxel
Oxaliplatin
Cisplatin
Bevacizumab

As we build our portfolio, we will add other drug candidates.